Press Releases
Press releases from hepCoalition and partner organizations.
Materials in this section
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More
Advocates Urge Cepheid to Reinstate Plans to Commercialize GeneXpert Omni
Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni. More
Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries
Hepatitis C PACT will work in Latin America, Asia, Africa, and Eastern Europe — collaborating with “champion countries” that are already revolutionizing hepatitis care. More
Advocates Demand Continuous Catalytic Investment Towards Viral Hepatitis Elimination
An open letter sent to Unitaid demands continuous investment towards HBV and HCV elimination, and to address the needs of 354 million people living with viral hepatitis worldwide. More
Advocates Demand Migrants’ Inclusion in EU and UK COVID-19 Vaccine Plans
An open letter sent to the UK and EU heads of state, and European Commission leadership urging for immediate provision of COVID-19 vaccines to all migrants residing in the UK and EU. More
Harnessing the COVID-19 Response Towards Hepatitis C Elimination
Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convened a virtual policy dialogue to share how COVID-19 has impacted global hepatitis C elimination efforts. More
Hepatitis C Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Nave Not Been Treated
Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits. More
Hepatitis C: Gilead Patent on Sofosbuvir Partially Maintained Following MdM Patent Opposition
Paris, 5 October 2016
European Patent Office (EPO) has taken its decision following Médecins du Monde (MdM) patent opposition on Gilead’s sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent. More
Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!
16 April 2016
People with HCV and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. More
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
On the eve of Gilead’s annual shareholder meeting, thousands of activists have demanded that Gilead change its policies that deny access to treatment for millions in developing countries. More
